BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol 2018;113:1678-88. [PMID: 30022113 DOI: 10.1038/s41395-018-0202-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Nielsen OH, Gubatan J, Juhl CB. Reply. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00512-7. [PMID: 33989789 DOI: 10.1016/j.cgh.2021.05.009] [Reference Citation Analysis]
2 Mountifield R. Anti-tumor necrosis factors (TNFs) are outdated-It's time to move on: Session three summary. J Gastroenterol Hepatol 2021;36 Suppl 1:25-6. [PMID: 33817852 DOI: 10.1111/jgh.15455] [Reference Citation Analysis]
3 Guerrero Vinsard D, Kane SV. Biologics and pregnancy: a clinician's guide to the management of IBD in pregnant women. Expert Rev Gastroenterol Hepatol 2021;15:633-41. [PMID: 33440996 DOI: 10.1080/17474124.2021.1876562] [Reference Citation Analysis]
4 Micu MC, Ostensen M, Bojincă V, Șerban O, Mihai M, Suța C, Ramazan A, Enache L, Bobircă A, Pătcaș SF, Micu R, Ionescu R. Pregnancy Outcomes in Couples with Males Exposed to Longterm Anti-tumor Necrosis Factor-α Inhibitor Therapies: A Prospective Study. J Rheumatol 2019;46:1084-8. [PMID: 30824658 DOI: 10.3899/jrheum.180588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang H, Chen F, Hu Y, Shen M. Adverse Pregnancy Outcomes Following Exposure to Biologics in Women With Crohn's Disease: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:753088. [PMID: 34760901 DOI: 10.3389/fmed.2021.753088] [Reference Citation Analysis]
6 Grišić AM, Dorn-Rasmussen M, Ungar B, Brynskov J, Ilvemark JFKF, Bolstad N, Warren DJ, Ainsworth MA, Huisinga W, Ben-Horin S, Kloft C, Steenholdt C. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. United European Gastroenterol J 2021;9:91-101. [PMID: 33079627 DOI: 10.1177/2050640620964619] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Truta B, Leeds IL, Canner JK, Efron JE, Fang SH, Althumari A, Safar B. Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:1110-7. [PMID: 31670762 DOI: 10.1093/ibd/izz250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 D'Amico F, Fiorino G, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L, Danese S. Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Rev Gastroenterol Hepatol 2020;14:765-73. [PMID: 32427002 DOI: 10.1080/17474124.2020.1772057] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Uyaroglu OA, Seyhoglu E, Erden A, Kilic L, Karadag O, Akdogan A, Bilgen SA, Ertenli AI, Kiraz S, Kalyoncu U. Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-α biologics: real-life results from a single-centre cross-sectional study. Rheumatol Int 2020;40:1501-7. [PMID: 31993731 DOI: 10.1007/s00296-020-04518-3] [Reference Citation Analysis]
10 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Malhi G, Tandon P, Perlmutter JW, Nguyen G, Huang V. Risk Factors for Postpartum Disease Activity in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021:izab206. [PMID: 34427643 DOI: 10.1093/ibd/izab206] [Reference Citation Analysis]
12 Selinger CP, Nelson-Piercy C, Fraser A, Hall V, Limdi J, Smith L, Smith M, Nasur R, Gunn M, King A, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. IBD in pregnancy: recent advances, practical management. Frontline Gastroenterol 2021;12:214-24. [PMID: 33912333 DOI: 10.1136/flgastro-2019-101371] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Leung KK, Tandon P, Govardhanam V, Maxwell C, Huang V. The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:550-62. [PMID: 32469057 DOI: 10.1093/ibd/izaa122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Perez-Garcia LF, Dolhain RJEM, Vorstenbosch S, Bramer W, van Puijenbroek E, Hazes JMW, Te Winkel B. The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review. Hum Reprod Update 2020;26:961-1001. [PMID: 32743663 DOI: 10.1093/humupd/dmaa022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
15 Tandon P, Govardhanam V, Leung K, Maxwell C, Huang V. Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:320-33. [DOI: 10.1111/apt.15587] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
16 Bröms G, Kieler H, Ekbom A, Gissler M, Hellgren K, Lahesmaa-Korpinen AM, Pedersen L, Schmitt-Egenolf M, Sørensen HT, Granath F. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 2020;29:316-27. [PMID: 32020767 DOI: 10.1002/pds.4930] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
17 Volger S, Scherl E. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00449-3. [PMID: 33864935 DOI: 10.1016/j.cgh.2021.04.015] [Reference Citation Analysis]
18 Meserve J, Luo J, Zhu W, Veeravalli N, Bandoli G, Chambers CD, Singh AG, Boland BS, Sandborn WJ, Mahadevan U, Singh S. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology 2021;161:107-115.e3. [PMID: 33744307 DOI: 10.1053/j.gastro.2021.03.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to Infliximab During Pregnancy: Post-Marketing Experience. Drug Saf 2020;43:147-61. [PMID: 31677004 DOI: 10.1007/s40264-019-00881-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
20 De Felice KM, Kane S. Safety of anti-TNF agents in pregnancy. J Allergy Clin Immunol 2021;148:661-7. [PMID: 34489011 DOI: 10.1016/j.jaci.2021.07.005] [Reference Citation Analysis]
21 Lai JH, Ling XC, Ho LJ. Useful message in choosing optimal biological agents for patients with autoimmune arthritis. Biochem Pharmacol 2019;165:99-111. [PMID: 30876919 DOI: 10.1016/j.bcp.2019.03.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Raine T, Gkini MA, Irving PM, Kaul A, Korendowych E, Laws P, Foulkes AC. Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists. BioDrugs 2021;35:187-99. [PMID: 33635522 DOI: 10.1007/s40259-020-00464-5] [Reference Citation Analysis]
23 Romano C, Esposito S, Ferrara R, Cuomo G. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 2020;20:49-62. [DOI: 10.1080/14712598.2020.1689953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
24 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 de Aragão MC, Beraldo RF, Marcondes MB, de Barros JR, Herrerias GSP, Saad-Hossne R, Baima JP, Sassaki LY. Management of inflammatory bowel disease and serum level of infliximab in newborn exposed to anti-TNF therapy during pregnancy: Case report and literature review. Medicine (Baltimore) 2021;100:e28274. [PMID: 34941109 DOI: 10.1097/MD.0000000000028274] [Reference Citation Analysis]
26 Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol 2021;12:621247. [PMID: 34122062 DOI: 10.3389/fphar.2021.621247] [Reference Citation Analysis]
27 Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31281-7. [PMID: 32931960 DOI: 10.1016/j.cgh.2020.09.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
28 Ghalandari N, Dolhain RJEM, Hazes JMW, van Puijenbroek EP, Kapur M, Crijns HJMJ. Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review. Drugs 2020;80:1699-722. [PMID: 32852745 DOI: 10.1007/s40265-020-01376-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Shannahan SE, Erlich JM, Peppercorn MA. Insights into the treatment of inflammatory bowel disease in pregnancy. Therap Adv Gastroenterol 2019;12:1756284819852231. [PMID: 31191713 DOI: 10.1177/1756284819852231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]